This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AutoSynVax, ASV Vaccine
The AutoSynVax (ASV) program targets cancer neoantigens with an autologous synthetic vaccine approach. By utilizing sequencing and bioinformatics, patient-specific tumor mutations are identified for rapid and accurate selection of neoantigens. The ASV platform generates synthetic peptide neoantigens complexed with heat shock proteins (HSPs) that shuttle these neoantigens to antigen presenting cells.
Few other details have been released, but the company notably acquired PhosImmune and its bank of phosphopeptide tumor targets (PTTs) in 2015.
Additional information available to subscribers only: